Abstract Background Artificial intelligence (AI) has potential to improve endoscopic diagnosis and outcome assessment in inflammatory bowel disease (IBD). However, robust AI models require large, labeled datasets with full-length, high-resolution endoscopic videos. Many existing endoscopic databases rely on retrospective sampling, isolated images, or lack clinical context, limiting their utility for AI systems development. Methods A prospective video databank was established at Montreal University Hospital Center (NCT06822616) with enrollment of IBD patients undergoing endoscopy since 2022. The databank follows FAIR principles: Findable, Accessible, Interoperable, and Reusable. All patients provided informed consent for data collection and subsequent use in AI system development. Video recordings were de-identified from acquisition, using study identifiers without protected health information, with all technical specifications optimized for AI training (full-length, full-frame videos in 1920 × 1080-pixel resolution and 60fps, YUV 4:2:2 chroma subsampling and 10-bit color depth). Consecutive IBD patients were enrolled, with videos linked with structured clinical documentation including withdrawal time and real-time documentation of abnormal findings. Segmental SES-CD and Rutgeerts score for Crohn’s disease, or Mayo Endoscopic Subscore (MES) for ulcerative colitis were captured. All polyps, lesions, stenosis, dysplasia, and biopsies were labeled and time-stamped by a research assistant during the endoscopy. Results As of October 2025, the databank includes 8512 endoscopic procedures including 1207 colonoscopies in IBD patients (mean age 47.8 years, 52.2% female). Of these, 474 patients had ulcerative colitis and 571 had Crohn’s disease (details on cohort characteristics provided in Table 1 and 2) with longitudinal data available for 212 patients. For each procedure up to 732 datapoints were captured, including 150 and 186 data points specific to Crohn’s disease and ulcerative colitis disease activity, respectively, capturing segmental endoscopic inflammation scores (Tables 1 and 2) and corresponding histopathology results. Polyps were detected in 275 cases (22.8%), for a total of 537 documented and characterized polyps across all IBD patients. Conclusion This prospective, FAIR-compliant databank of 1,200 IBD patients provides a high-quality, scalable foundation for the development and validation of AI systems in endoscopic diagnosis and clinical outcomes research. Ongoing expansion to additional centers, together with incorporation of digital pathology images and multi-omics data, will establish a comprehensive multimodal databank designed for AI based precision medicine in IBD. Conflict of interest: Ms. Oleksiw, Megan: No conflict of interest Battat, Robert: Speaker/consulting/moderator: Bristol Myers Squibb, Johnson and Johnson Innovative Medicine, AbbVie, Takeda, Ferring, Celltrion, Pfizer, Merck, Eli Lilly Advisory boards: Celltrion, AbbVie, Pfizer, Janssen, Bristol Myers Squibb, Takeda, Merck, Eli Lilly Educational grants and educational sponsorships: Abbvie, Johnson and Johnson Innovative Medicine, Pfizer, Eli Lilly, Amgen, Pendopharm, Kye Pharma, Merck, Celltrion, Organon, Takeda Travel support: Pfizer, Celltrion, Johnson and Johnson Innovative Medicine, Abbvie. Michal, Victoire: No conflict of interest Daoud, Dane Christina: No conflict of interest Bernard, Edmond-Jean: No conflict of interest Orlicka, Katarzyna: No conflict of interest Leduc, Raymond: No conflict of interest Daoust, Louise: No conflict of interest Liu Chen Kiow, Jeremy: No conflict of interest Djinbachian, Roupen: Roupen Djinbachian has received speaker fees from Fujifilm. Deslandres, Erik: No conflict of interest Bouin, Mickael: No conflict of interest Panzini, Benoit: No conflict of interest Bouchard, Simon: No conflict of interest von Renteln, Daniel: Daniel von Renteln is supported by a “Fonds de Recherche du Québec Santé” career development award. He has also received research funding from ERBE Elektromedizin GmbH, Ventage, Pendopharm, Fujifilm and Pentax, and has received consultant or speaker fees from Boston Scientific Inc., ERBE Elektromedizin GmbH, and Pendopharm.
Oleksiw et al. (Thu,) studied this question.